Inhibikase Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Inhibikase Therapeutics

01/04/2022 21:58

* Inhibikase Therapeutics Inc  IKT.OQ  reported a quarterly
adjusted loss of 20 cents​​ per share for the quarter ended in
December. The lone analyst forecast for the quarter was for a
loss of 17 cents per share.
    * Revenue was $1.94 thousand​;  analysts expected $300.00
thousand. 
    * Inhibikase Therapeutics Inc's reported EPS for the quarter
was a
loss of 20 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Inhibikase Therapeutics Inc shares had held steady so far
this
quarter and gained 0.7% so far this year.
    * The company reported a quarterly loss of $5.04 million.
    * Wall Street's median 12-month price target for Inhibikase
Therapeutics Inc is $10.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated April 1 at 08:58 p.m.  ​All
figures in US dollars unless otherwise stated